Company Deep Dive
Business segments breakdown, earnings transcript analysis, management credibility scoring, competitive landscape, and scenario modelling.
PYXS
STRONG SELLPyxis Oncology, Inc. · Healthcare · United States · $165M · Avg Vol: $4M/d
14
StockRankGet insider-trade alerts
Q
20
V
25
M
49
P/E (TTM)
—
ROE
-121.7%
D/E
0.6x
Dividend %
—
Loading 1Y...
PRICE (1Y)+65.3%
SMA 50SMA 200
Close
$2.91
RSI (14)
46.5
52W High
$5.55
From 52W High
0.5%
SCORE BREAKDOWN
Quality
20
ROIC
-122.0%4.8
ROE
-121.7%7.5
GP/Assets
12.5%32.0
Op. Margin
-600.2%9.7
FCF/Assets
-69.4%3.3
Piotroski
239.0
Int. Cover
—N/A
D/E Ratio
0.58x26.9
Current Ratio
2.76x50.5
Value
25
P/E (TTM)
—N/A
EV/EBITDA
-1.8x25.0
P/FCF
—N/A
P/B
5.2x25.7
P/S
11.9x24.0
Div Yield
—N/A
Momentum
49
52W High %
52%28.7
RS 6M
71%96.2
SMA 50/200
0.93x48.1
EPS Rev 4W
—N/A
EPS Rev 12W
—N/A
EPS Improve
+7%26.4
Q Growth
—N/A
FUNDAMENTALS
Market Cap
$165M
P/E (Forward)
-2.2x
Gross Margin
82.8%
SECTOR PEERS
Closest peers in Healthcare, ranked by industry match, size, and score similarity. Cross-listings of PYXS are excluded.
| Ticker | Company | Mkt Cap | StockRank | Signal |
|---|---|---|---|---|
| PYXS | Pyxis Oncology, Inc.(you) | $165M | 14 | STRONG SELL |
| TNYA | Tenaya Therapeutics, Inc. | $168M | 15 | STRONG SELL |
| CRBP | Corbus Pharmaceuticals Holdings, Inc. | $170M | 15 | STRONG SELL |
| ARCT | Arcturus Therapeutics Holdings Inc. | $157M | 15 | STRONG SELL |
| ABOS | Acumen Pharmaceuticals, Inc. | $154M | 15 | STRONG SELL |
| CNTN | Canton Strategic Holdings, Inc. | $150M | 15 | STRONG SELL |
| UNCY | Unicycive Therapeutics, Inc. | $148M | 14 | STRONG SELL |
| TNXP | Tonix Pharmaceuticals Holding Corp. | $157M | 12 | STRONG SELL |
| VYGR | Voyager Therapeutics, Inc. | $187M | 15 | STRONG SELL |
| KRRO | Korro Bio, Inc. | $153M | 12 | STRONG SELL |
Peer medians: ROE -25.5% · P/E 27.6x · Gross margin 50.5%